CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Summary

This is a multicenter, prospective, randomized controlled clinical study comparing the efficacy and safety of CLAG+VEN and CLAG regimens in relapsed/refractory(r/r) AML.

Conditions

• Relapsed/Refractory AML

Interventions

DRUG

Cladribine

Given IV

DRUG

Cytarabine

Given IV

DRUG

G-CSF

Given SC

DRUG

Venetoclax

Given PO

Sponsors & Collaborators

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  collaborator OTHER

• Guangzhou No.12 People's Hospital

  collaborator OTHER_GOV

• Guangzhou Panyu Central Hospital

  collaborator OTHER

• Guangzhou General Hospital of Guangzhou Military Command

  collaborator OTHER

• Guangzhou First People's Hospital

  collaborator OTHER

• Foresea Life Insurance Guangzhou General Hospital

  collaborator UNKNOWN

• Guangdong Second Provincial General Hospital

  collaborator OTHER

• Jiangmen Central Hospital

  collaborator OTHER

• Shantou Central Hospital

  collaborator OTHER

• Maoming People's Hospital

  collaborator OTHER

• First Affiliated Hospital of Guangxi Medical University

  collaborator OTHER

• Hainan General Hospital

  collaborator OTHER

• Dongguan People's Hospital

  collaborator OTHER_GOV

• Tungwah Hospital of Sun Yat-Sen University

  collaborator UNKNOWN

• Shenzhen Hospital of Southern Medical University

  collaborator OTHER

• Central People's Hospital of Zhanjiang

  collaborator OTHER

• ZhuHai Hospital

  collaborator OTHER

• Shenzhen Second People's Hospital

  collaborator OTHER

• Zhongshan People's Hospital, Guangdong, China

  collaborator OTHER

• LiuZhou People's Hospital

  collaborator OTHER

• First People's Hospital of Foshan

  collaborator OTHER

• Southern Medical University, China

  collaborator OTHER

• Affiliated Hospital of Guangdong Medical University

  collaborator OTHER

• Guilin Medical University, China

  collaborator OTHER

• Yuebei People's Hospital

  collaborator OTHER

• Huizhou Municipal Central Hospital

  collaborator OTHER

• Second Affiliated Hospital of Guangzhou Medical University

  collaborator OTHER

• Peking University Shenzhen Hospital

  collaborator OTHER

• Nanfang Hospital, Southern Medical University

  lead OTHER

Principal Investigators

• Guopan Yu · Nanfang Hospital, Southern Medical University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-02-28

Primary Completion

2025-06-30

Completion

2025-12-31

Countries

• China

Study Locations